Boston Scientific (BSX) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts BSX Hot Sheet
Price: $47.80 +1.81%
Revenue Growth %: +3.7%
Financial Fact:
Operating income (loss): 348M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +3.7%
Financial Fact:
Operating income (loss): 348M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.34, in-line with the analyst estimate of $0.34. Revenue for the quarter came in at $2.41 billion versus the consensus estimate of $2.38 billion.
For earnings history and earnings-related data on Boston Scientific (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance
- John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
